Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations.
Nat Commun · 2025-Dec-03 · PMID 41339316
PFS
Fig. 3. Association between clinical outcomes with atezolizumab-bevacizumab-chemotherapy combinations and NMF subtype in IMpower150. a PFS in each treatment arm by NMF subtype. The forest plot shows the PFS HRs for ABCP vs BCP for each subtype. b OS in each treatment arm by NMF subtype. The forest plot shows the OS HRs for ABCP vs BCP. c Comparison of PFS across NMF subtypes by treatment. d Comparison of PFS (top 3 panels) and OS (bottom 3 panels) with ABCP vs BCP in NMF2 and NMF4 subtypes by PD-L1 level: PD-L1–high (tumour proportion score ≥ 50% by SP263 IHC assay), PD-L1–low (1%-49%) and PD-L1–negative (< 1%). Data in the ACP arm were not substantially different from those in the BCP arm and are not shown in the graphs to aid visualization. e Results of the multivariate analysis evaluating the association between the outcomes (PFS: left panel, and OS: right panel) and multiple factors on the ABCP arm. These factors include NMF subtypes, PD-L1 levels, tumor mutation burden, STK11/KEAP1 mutational status, and smoking history. Source data are provided as a Source Data file. For the forest plots in a,b , e , each row represents a different predictor variable, with the point estimates and 95% CIs for the HRs displayed as squares and horizontal error bars, respectively. The vertical dashed line represents the line of no effect (HR = 1.0). Variables with confidence intervals that do not cross this line are considered statistically significant. For the survival analyses in a , b , e , the log-rank test was used to compare Kaplan-Meier survival curves. Cox proportional hazards regression models were used to generate hazard ratios and 95% confidence intervals. Multivariable Cox proportional hazards regression models were used to compare the interdependence of distinct biomarkers for prediction of OS benefit. ABCP atezolizumab plus bevacizumab plus carboplatin-paclitaxel, ACP atezolizumab plus carboplatin-paclitaxel, BCP bevacizumab plus carboplatin-paclitaxel, NE not estimable.
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | quality_warning | 待验证 | 1 | 2026-07-23T17:08:08+00:00 |